

## REMARKS

The Non-Compliant Amendment mailed on February 8, 2005 did not take into account the Response to Non-Compliant Amendment mailed on February 4, 2005. In a telephone conversation with Examiner Marianne DiBrino on March 11, 2005 and pursuant to her request, Applicants hereby resubmit the Response to Non-Compliant Amendment of February 4, 2005 for consideration.

An abstract was not provided with this application as originally filed due to ministerial error. The original abstract, entitled "Abstract of the Disclosure", is attached herewith for entry. Applicants further request that the "Amendments to the Abstract" be entered so the Abstract does not exceed 150 words in length in compliance with 37 CFR 1.72(b). No new matter is introduced by the amendments contained herein.


Applicants submit that the claims are in form for allowance and early notice of such is requested. If the Examiner believes that there are remaining issues which may be resolved by telephone, he is invited to call the undersigned at (415) 781-1989.

Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

DORSEY & WHITNEY LLP

Dated: April 4, 2005

By:   
Michael Kolman, Reg. No. 54,234 for  
Todd A. Lorenz, Reg. No. 39,754

**Customer No.: 32940**

DORSEY & WHITNEY LLP

Four Embarcadero Center, Suite 3400

San Francisco, CA 94111-4187

Telephone: (415) 781-1989

Fax No. (415) 398-3249

1163186\_1.DOC

Attachments:

Abstract of the Disclosure

Response to Non-Compliant Amendment filed on February 4, 2005



## **CYTOMODULATING LIPOPHILIC PEPTIDES FOR MODULATING IMMUNE SYSTEM ACTIVITY AND INHIBITING INFLAMMATION**

### **ABSTRACT OF THE DISCLOSURE**

Novel oligopeptides comprising a sequence derived by a computer program are provided for use in inhibiting cytotoxic activity of lymphocytic cells, inhibiting the production of inflammatory cytokines and inflammatory responses associated with those cytokines, inhibiting the activity of heme-containing enzymes and delaying the onset of an autoimmune disease in a mammal at risk of developing the disease. By combining the subject compositions with mixtures of cells comprising lymphocytic cells and cells which would otherwise activate the lymphocytic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a wide variety of other groups or compounds for varying the activity of the subject compositions. The subject compositions may be administered by any convenient means to a host to inhibit lymphocytic attack on tissue, particularly involved with xenogeneic or allogeneic transplants or to inhibit the production of inflammatory cytokines and inflammatory responses associated therewith. The subject compositions may also be used in the inhibition of the activity of heme-containing enzymes.